NASDAQ:BCLIBrainstorm Cell Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Brainstorm Cell Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $12.82 -0.43 (-3.25 %) (As of 07/14/2020 04:00 PM ET) Add Compare Share Today's Range$12.75Now: $12.82▼$13.9750-Day Range$6.51MA: $10.01▼$13.2552-Week Range$3.43Now: $12.82▼$13.97Volume1.32 million shsAverage Volume666,586 shsMarket Capitalization$377.43 millionP/E RatioN/ADividend YieldN/ABeta1.12 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient's own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival. It is developing NurOwn for various neurodegenerative diseases, including its lead indication, which is in Phase III clinical trial for the treatment of amyotrophic lateral sclerosis, as well as in preclinical trial for the treatment of multiple sclerosis, Parkinson's disease, Huntington's disease, and autism spectrum disorder. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in New York, New York.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingBrainstorm Cell Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $20.00, Brainstorm Cell Therapeutics has a potential upside of 56.0% from its current price of $12.82.Amount of Analyst CoverageBrainstorm Cell Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 2.9 Community Rank Outperform VotesBrainstorm Cell Therapeutics has received 282 “outperform” votes. (Add your “outperform” vote.)Underperform VotesBrainstorm Cell Therapeutics has received 196 “underperform” votes. (Add your “underperform” vote.)Community SentimentBrainstorm Cell Therapeutics has received 59.00% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Brainstorm Cell Therapeutics and other stocks. Vote “Outperform” if you believe BCLI will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BCLI will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldBrainstorm Cell Therapeutics does not currently pay a dividend.Dividend GrowthBrainstorm Cell Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Brainstorm Cell Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 21.20% of the stock of Brainstorm Cell Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 12.59% of the stock of Brainstorm Cell Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Brainstorm Cell Therapeutics are expected to grow in the coming year, from ($1.10) to ($0.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Brainstorm Cell Therapeutics is -11.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Brainstorm Cell Therapeutics is -11.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.41 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BCLI Previous Symbol CUSIPN/A CIK1137883 Webwww.brainstorm-cell.com Phone201-488-0460Debt Debt-to-Equity Ratio0.09 Current Ratio1.84 Quick Ratio1.84Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.54) per share Price / Book-23.74Profitability EPS (Most Recent Fiscal Year)($1.06) Net Income$-23,250,000.00 Net MarginsN/A Return on EquityN/A Return on Assets-255.23%Miscellaneous Employees31 Outstanding Shares29,441,000Market Cap$377.43 million Next Earnings Date8/11/2020 (Estimated) OptionableOptionable NASDAQ:BCLI Rates by TradingView Receive BCLI News and Ratings via Email Sign-up to receive the latest news and ratings for BCLI and its competitors with MarketBeat's FREE daily newsletter. Brainstorm Cell Therapeutics (NASDAQ:BCLI) Frequently Asked Questions How has Brainstorm Cell Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Brainstorm Cell Therapeutics' stock was trading at $6.68 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, BCLI stock has increased by 91.9% and is now trading at $12.82. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Brainstorm Cell Therapeutics? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Brainstorm Cell Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Brainstorm Cell Therapeutics. When is Brainstorm Cell Therapeutics' next earnings date? Brainstorm Cell Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Brainstorm Cell Therapeutics. How were Brainstorm Cell Therapeutics' earnings last quarter? Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) released its quarterly earnings results on Thursday, May, 7th. The biotechnology company reported ($0.32) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.23) by $0.09. View Brainstorm Cell Therapeutics' earnings history. What price target have analysts set for BCLI? 1 analysts have issued twelve-month price objectives for Brainstorm Cell Therapeutics' stock. Their forecasts range from $20.00 to $20.00. On average, they anticipate Brainstorm Cell Therapeutics' stock price to reach $20.00 in the next year. This suggests a possible upside of 56.0% from the stock's current price. View analysts' price targets for Brainstorm Cell Therapeutics. Has Brainstorm Cell Therapeutics been receiving favorable news coverage? News coverage about BCLI stock has been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Brainstorm Cell Therapeutics earned a media sentiment score of 2.0 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the immediate future. View the latest news about Brainstorm Cell Therapeutics. Who are some of Brainstorm Cell Therapeutics' key competitors? Some companies that are related to Brainstorm Cell Therapeutics include SpringWorks Therapeutics (SWTX), Sangamo Therapeutics (SGMO), Adverum Biotechnologies (ADVM), Legend Biotech (PCVX), Regenxbio (RGNX), Beam Therapeutics (BEAM), Mesoblast (MESO), Nantkwest (NK), Coherus Biosciences (CHRS), NanoString Technologies (NSTG), Cortexyme (CRTX), Adaptimmune Therapeutics (ADAP), Translate Bio (TBIO), I-Mab (BDTX) and Compugen (CGEN). View all competitors. What other stocks do shareholders of Brainstorm Cell Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Brainstorm Cell Therapeutics investors own include Organovo (ONVO), Gene Biotherapeutics (CRXM), Protalix Biotherapeutics (PLX), Anavex Life Sciences (AVXL), Sangamo Therapeutics (SGMO), IsoRay (ISR), Mellanox Technologies (MLNX), Caladrius Biosciences (CLBS), Abeona Therapeutics (ABEO) and Adaptimmune Therapeutics (ADAP). Who are Brainstorm Cell Therapeutics' key executives? Brainstorm Cell Therapeutics' management team includes the following people: Dr. Irit Arbel, Founder & Chairperson (Age 59)Mr. Chaim Lebovits, Pres & CEO (Age 48)Mr. Eyal Rubin, CFO & Treasurer (Age 43)Dr. Ralph Z. Kern, COO & Chief Medical Officer (Age 61)Mr. Uri Yablonka, Exec. VP, Chief Bus. Officer & Director (Age 42) What is Brainstorm Cell Therapeutics' stock symbol? Brainstorm Cell Therapeutics trades on the NASDAQ under the ticker symbol "BCLI." Who are Brainstorm Cell Therapeutics' major shareholders? Brainstorm Cell Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Abner Herrman & Brock LLC (0.81%). Company insiders that own Brainstorm Cell Therapeutics stock include Irit Arbel, June Sherie Almenoff, Preetam Shah and Ralph Dr Kern. View institutional ownership trends for Brainstorm Cell Therapeutics. Which institutional investors are buying Brainstorm Cell Therapeutics stock? BCLI stock was acquired by a variety of institutional investors in the last quarter, including Abner Herrman & Brock LLC. Company insiders that have bought Brainstorm Cell Therapeutics stock in the last two years include June Sherie Almenoff, Preetam Shah, and Ralph Dr Kern. View insider buying and selling activity for Brainstorm Cell Therapeutics. How do I buy shares of Brainstorm Cell Therapeutics? Shares of BCLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Brainstorm Cell Therapeutics' stock price today? One share of BCLI stock can currently be purchased for approximately $12.82. How big of a company is Brainstorm Cell Therapeutics? Brainstorm Cell Therapeutics has a market capitalization of $377.43 million. The biotechnology company earns $-23,250,000.00 in net income (profit) each year or ($1.06) on an earnings per share basis. Brainstorm Cell Therapeutics employs 31 workers across the globe. What is Brainstorm Cell Therapeutics' official website? The official website for Brainstorm Cell Therapeutics is www.brainstorm-cell.com. How can I contact Brainstorm Cell Therapeutics? Brainstorm Cell Therapeutics' mailing address is 1325 AVENUE OF AMERICAS 28TH FLOOR, NEW YORK NY, 10019. The biotechnology company can be reached via phone at 201-488-0460 or via email at [email protected] This page was last updated on 7/15/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
